
    
      16 subjects with 2 dose groups will be enrolled in the study, all of whom received the
      SHR-1314 without placebo control. There are 8 subjects in each cohort. The dose will be
      started at 160mg and will be escalated by following dose escalating rules. The primary
      endpoint is the safety and tolerability : adverse events, vital signs, physical examination,
      laboratory examination, 12 lead electrocardiogram, injection site reactions, etc.
    
  